Portal hypertension: From pathophysiology to clinical practice

Liver International

Volumn 25, Issue 6, 2005, Pages 1079-1090

  Laleman, Wim ^a   Van Landeghem, Lien ^a   Wilmer, Alexander ^a   Fevery, Johan ^a   Nevens, Frederik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Intrahepatic vascular resistance; Pathophysiology; Pharmacotherapy; Portal hypertension; Review

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARVEDILOL; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE 5 NITRATE; LOSARTAN; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PRAZOSIN; PROSTACYCLIN; PROSTAGLANDIN E2; PROTEIN KINASE B; RHO FACTOR; SOMATOSTATIN; TEZOSENTAN; UNINDEXED DRUG; VASOPRESSIN DERIVATIVE;

ANGIOGENESIS; BLOOD VESSEL TONE; CLINICAL PRACTICE; DRUG MECHANISM; ESOPHAGUS VARICES BLEEDING; GENE THERAPY; GENE TRANSFER; HUMAN; HYPEREMIA; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; REVIEW; RISK REDUCTION; STOMACH VARICES; SURVIVAL RATE; VASCULAR RESISTANCE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRCULATION; LIVER CIRRHOSIS; VASCULAR RESISTANCE;

EID: 28944437539     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01163.x     Document Type: Review

References (114)

1. Wongcharatrawee S, Groszmann R J. Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 881-94.
2. Ramesh S, Sanyal A J. Hepatitis C and nonalcoholic fatty liver disease. Semin Liv Dis 2004; 24: 399-413.
3. Myers J D, Taylor W J. An estimation of portal venous pressure by occlusive catherization of a hepatic venule. J Clin Invest 1951; 30: 662-3.
4. Groszmann R J, Wongcharatwee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2003; 39: 280-2.
5. Garcia-Tsao G, Groszmann R J, Fisher R L, Conn H O, Atterbury C E, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419-24.
6. Casado M, Bosch J, Garcia-Pagan J C, Bru C, Banares R, Bandi J C, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-303.
7. Vorobioff J, Groszmann R J, Picabea E, Gamen M, Villavicencio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 11: 701-9.
8. Groszmann R J, Bosch J, Grace N D, Conn H O, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 90: 1401-7.
9. Feu F, Garcia-Pagan J C, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9.
10. Escorsell A, Bordas J M, Castaneda B, Llach J, Garcia-Pagan J C, Rodes J, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061-7.
11. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini D, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32: 930-4.
12. Villanueva C, Balanzo J, Novella M T, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the therapy for prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624-9.
13. Abraldes J G, Tarantino I, Turnes J, Garcia-Pagan J C, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.
14. Lebrec D, Poynard T, Hillon P, Benhamou J P. Propanolol for the prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 1981; 305: 1371-4.
15. Pascal J P, Cales P. Propanolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317: 856-61.
16. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
17. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liv Dis 1999; 19: 475-505.
18. Villeneuve J P, Pomier-Layrargues G, Infante-Rivard C, Willems B, Huet P M, Marleau D, et al. Propanolol for the prevention of recurrent variceal rebleeding in cirrhosis: a controlled trial. Hepatology 1986; 6: 1239-43.
19. Bosch J, Garcia-Pagan J C. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32(Suppl. 1): 141-56.
20. Bosch J, Groszmann RJ, eds. Portal Hypertension: Pathophysiology and Treatment. Oxford: Blackwell, 1994.
21. Bhathal P S, Grossman H J. Reduction of the increased intrahepatic vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325-37.
22. Pinzani M, Failli P, Ruocco C, Casini A, Milani S, Baldi E, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992; 90: 642-6.
23. Kawada N, Tran-Thi T A, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin-1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993; 213: 815-23.
24. Rockey D C, Housset C N, Friedman S L. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993; 92: 1795-804.
25. Cassiman D, Roskams T. Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J Hepatol 2002; 37: 527-35.
26. Friedman S L. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-35.
27. Zhang J X, Pegoli W J, Clemens M G. Endothelin-1 induces direct constriction of the hepatic sinusoids. Am J Physiol 1994; 266: G624-32.
28. Rockey D C. Vascular mediators in the injured liver. Hepatology 2003; 37: 4-12.
29. Graupera M, Garcia-Pagan J C, Titos E, Claria J, Massaguer A, Bosch J, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 2002; 122: 387-93.
30. Ghandi C R, Sproat L A, Subbotin V M. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci 1996; 58: 55-62.
31. Rockey D C, Chung J J. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 1996; 98: 1381-8.
32. Cho J J, Hocher B, Herbst H, Jia J D, Ruehl M, Hahn E G, et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000; 118: 1169-78.
33. Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-Lopez F, Rodes J. Effect of angiotensin-II blockade on systemic and hepatic hemodynamics and on the reninangiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981; 11: 221-9.
34. Bataller R, Gines P, Nicolas J M, Gorbig M N, Garcia-Ramallo E, Gasull X, et al. Angiotensin induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
35. Bataller R, Gines P, Lora J, Sole M, Nicolas J M, Jimenez W. Evidence for a local renin-angiotensin system in human liver: expression in activated hepatic stellate cells. Hepatology 2001; 34: 399A.
36. Bataller R, Schwabe R F, Choi Y H, Yang L, Paik Y H, Lindquist J, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003; 112: 1383-94.
37. Oben J A, Roskams T, Yang S, Lin H, Sinelli N, Torbenson M, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 2004; 53: 438-45.
38. Van DE Casteele M, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002; 51: 440-5.
39. Shah V J, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 1222-8.
40. Moralez-Ruiz M, Cejudo-Martin P, Fernandez-Varo G, Tugues S, Ros J, Angeli P, et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 2003; 125: 522-31.
41. Rockey D C, Chung J J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114:344-51.
42. Van de Casteele M, Van Pelt J F, Nevens F, Fevery J, Reichen J. Low NO bioavailability in CC14 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2003; 2: 2.
43. Suematsu M, Goda N, Sano T, Kashiwaga S, Egawa T, Shinoda Y, et al. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 1995; 96: 2431-6.
44. Maines M D. Heme oxygenase: function, multiplicity, regulation mechanism and clinical applications. FASEB J 1988; 2: 2557-68.
45. McCoubry W K Jr., Huang T J, Maines M D. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 1997; 247: 725-32.
46. Goda N, Suzuki K, Naito M, Takeoka S, Tsuchida E, Ishimura Y, et al. Distribution of heme oxygenase isoforms in rat liver. Topographic basis of carbon monoxide-mediated microvascular relaxation. J Clin Invest 1998; 101: 604-12.
47. Suematsu M, Wakabayashi Y, Ishimura Y. Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovas Res 1996; 32: 679-86.
48. Vorobioff J, Bredfeldt J, Groszmann R J. Hyperdynamic circulation in a portal hypertensive rat model: a primary factor for the maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-6.
49. Wiest R, Groszmann R J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-91.
50. Sikuler E, Groszmann R J. Interaction of flow and resistance in maintenace of portal hypertension in a rat model. Am J Physiol 1986; 250: G205-12.
51. Möller S, Bendtsen F, Henriksen J H. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001; 61: 421-30.
52. Benoit J N, Barrowman J A, Harper S L, Kvietys P R, Granger D N. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984; 247: E486-93.
53. Genecin P, Polio J, Colombato L A, Ferraioli G, Reuben A, Groszmann R J. Role of bile acids do not mediate the hyperdynamic circulation in portal hypertensive rats. Am J Physiol 1990; 259: G21-5.
54. Thomas S H, Joh T, Benoit J N. Role of bile acids in splanchnic hemodynamic response to chronic portal hypertensive rats. Dig Dis Sci 1991; 36: 1243-8.
55. Fernandez M, Casadevall M, Schuligoi R, Pizcueta P, Panes J, Barrachina M D, et al. Neonatal capsaicin treatment does not prevent splanchnic vasodilation in portal hypertensive rats. Hepatology 1994; 20: 1609-14.
56. Lee S S, Sharkey K A. Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive rats. Am J Physiol 1993; 264: G868-73.
57. Gomis R, Fernandez-Alvarez J, Pizcueta P, Fernandez M, Casamitjana R, Bosch J, et al. Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial vein ligation. Hepatology 1994; 19: 1257-61.
58. Silva G, Navasa M, Bosch J, Chesta J, Pilar Pizcueta M, Casamitjana R, et al. Hemodynamic effects of glucagon in portal hypertension. Hepatology 1990; 11: 668-73.
59. Kravetz D, Bosch J, Arderiu M T, Pizcueta M P, Casamitjana R, Rivera F, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagons in portal hypertensive rats. Am J Physiol 1988; 254: G322-5.
60. Benoit J N, Zimmerman B, Premen A J, Go V L, Granger D N. Role of glucagons in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986; 251: G674-8.
61. Fernandez M, Garcia-Pagan J C, Casadevall M, Mourelle M I, Pique J M, Bosch J, et al. Acute and chronic cyclooxygenase blockade in portal hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology 1996; 110: 1529-35.
62. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 1: 776.
63. Martin P, Xu D, Niederberger M, Weigert A, Tsai P, St John J, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996; 270: F494-9.
64. Fernandez M, Garcia-Pagan J C, Casadevall M, Bernadich C, Piera C, Whittle B J, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats. Gastroenterology 1995; 108: 1487-95.
65. Wiest R, Shah V J, Sessa W, Groszmann R J. Nitric oxide overproduction by eNOS precedes the hyperdynamic circulation in portal hypertensive rats. Am J Physiol 1999; 276: G1043-51.
66. Cahill P A, Redmond E M, Hodges R, Zhang S, Sitzmann J V. Increased endothelial nitric oxide synthase activity in the hyperaemic vessels of portal hypertensive rats. J Hepatol 1996; 25: 370-8.
67. Pateron D, Tazi K A, Sogni P, Heller J, Chagneau C, Poirel O, et al. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 2000; 119: 1996-2000.
68. Braillon A, Lee S, Girod C, Peignoux-Martinot M, Valla D, Lebrec D. Role of portosystemic shunts in the hyperkinetic circulation of the portal hypertensive rat. J Lab Clin Med 1986; 108: 543-8.
69. Tazi K A, Barriere E, Moreau R, Heller J, Sogni P, Pateron D, et al. Role of shear stress in aortic eNOS upregulation in rats with bilairy cirrhosis. Gastroenterology 2002; 122: 1869-77.
70. Akiyoshi F, Sata M, Suzuki H, Uchimura Y, Mitsuyama K, Matsuo K, et al. Serum vascular endothelial growth factor levels in various liver diseases. Dig Dis Sci 1998; 43: 41-5.
71. Bouloumie A, Schini-Kerth V B, Busse R. Vascular endothelial growth factour up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41: 509-10.
72. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann R J. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
73. Fernandez M, Lambrecht R W, Bonkovsky H. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. J Hepatol 2001; 34: 812-7.
74. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharm Ther 2001; 89: 221-31.
75. Henriksen J H, Kizska-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16: 12-23.
76. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Light and shadows in an important clinical problem. J Hepatol 2000; 32: 157-70.
77. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
78. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46-52.
79. Yu Q, Shao R, Qian H S, George S E, Rockey D C. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741-8.
80. Rockey D C. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin Liv Dis 2001; 5: 851-65.
81. Zafra C, Abraldes J G, Turnes J, Berzigotti A, Fernandez M, Garcia-Pagan J C, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749-55.
82. Yanase M, Ikeda H, Matsui A, Noiri E, Tomiya T, Arai M, et al. HMG-COA reductase inhibitor modulates collagen gel-contraction by hepatic myofibroblast-like stellate cell line: involvement of geranylgeranylated proteins. Comp Hepatol 2004; 3: S21.
83. Moal F, Vuillemin E, Wang J, Veal N, Oberti F, Cales P. Chronic antifibrotic and hemodynamic effects of a new liver specific NO donor (V-pyrro/NO) in bile duct ligated rats. Hepatology 2001; 32: 186A.
84. Fiorucci S, Antonelli E, Morelli O, Mencabelli A, Casini A, Mello T, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the live rand protects against development of portal hypertension. Proc Natl Acad Sci USA 2001; 98: 8897-902.
85. Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distributti E, et al. NCX-1000, a nitric oxide releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003; 39: 932-9.
86. Loureira-Silva M R, Cadelina G W, Iwakiri Y, Groszmann R J. A liver-specific nitric oxide donor improves the intrahepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003; 39: 940-6.
87. Fernando B, Marley R, Holt S, Anand R, Harry D, Sanderson P, et al. N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. Hepatology 1998; 28: 689-94.
88. Marley R, Holt S, Fernando B, Harry D, Anand R, Goodier D, et al. Lipoic acid prevents the development of the hyperdynamic circulation in anesthetized rats with biliary cirrhosis. Hepatology 1999; 29: 1358-63.
89. Kojima H, Sakurai S, Kuriyama S, Yoshiji H, Imazu H, Uemura M, et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B togheter with subtype A in vivo. J Hepatol 2001; 34: 805-11.
90. Reichen J, Gerbes A L, Steiner M J, Sagesser H, Clozel M. The effect of endothelin and its agonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998; 28: 1020-30.
91. Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, et al. Beneficial effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998; 28: 655-9.
92. Poo J L, Jimenez W, Maria M R, Bosch-Marce M, Bordas N, Morales-Ruiz M, et al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology 1999; 116: 161-7.
93. Cho J J, Hocher B, Herbst H, Jia J D, Ruehl M, Hahn E G, et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000; 118: 1169-78.
94. Channick R N, Sitbon O, Barst R J, Manes A, Rubin L J. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 62-7S.
95. Sanyal A J. Angiotensin receptor blockade and portal hypertension: paradise gained, paradise lost. Gastroenterology 2001; 121: 487-90.
96. Schneider A W, Friedrich J, Klein C P. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-9.
97. Schepke M, Werner E, Bieker E, Schiedermaieer P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389-95.
98. Gonzalez-Abraldes J, Albilos A, Banares R, Del Arbol L R, Moitinho E, Rodriguez C, et al. Randomized comparison of long-term losartan versus propanolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-8.
99. Debernardi-Venon W, Barletti C, Alessandria C, Marzano A, Baronio M, Todros L, et al. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci 2002; 47: 401-4.
100. Friedman S L. The answer: angiotensin II. The question: what do inflammation, oxidant stress and fibrogenesis have in common. J Hepatol 2004; 40: 1050-2.
101. Albillos A, Lledo J L, Banares R, Rossi I, Iborra J, Calleja J L, et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994; 20: 611-7.
102. Albillos A, Lledo J L, Rossi I, Perez-Paramo M, Tabuenca M J, Banares R, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109: 1257-65.
103. Albillos A, Garcia-Pagan J C, Iborra J, Bandi JC, Cacho G, Perez-Paramo M, et al. Propanolol plus prazosin compared with propanolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998; 115: 116-23.
104. Frishman W H. Carvedilol. N Engl J Med 1998; 339: 1759-65.
105. Hemstreet B A. Evaluation of carvedilol for the treatment of portal hypertension. Pharmacotherapy 2004; 24: 94-104.
106. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981; 80: 518-25.
107. Reynaert H, Geerts A. Review article: pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 2003; 18: 375-86.
108. Reynaert H, Vaeyens F, Qin H, Hellemans K, Chatterjee N, Winand D, et al. Somatostatin suppresses endothelin-1-induced rat hepatic stellate cell contraction via somatostatin receptor subtype 1. Gastroenterology 2001; 121: 915-30.
109. Abraldes J G, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology 2002; 35: 1305-12.
110. Nakabayashi H, Kurata Y, Usukura N, Takeda R. Somatostatin-sensitive neural system in the liver. Neurosci Lett 1986; 67: 78-81.
111. Nevens F. Review article: a critical comparison of drug therapies in currently used therapeutic strategies for variceal haemorrhage. Aliment Pharmacol Ther 2004; 20(Suppl. 3): 18-22.
112. Pilette C, Kirstetter P, Sogni P, Cailmail S, Moreau R, Lebrec D. Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. J Gastroenterol Hepatol 1996; 11: 1-6.
113. Pizcueta P, Pique J M, Fernandez M, Bosch J, Rodes J, Whittle B J. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-15.
114. Forrest E H, Jones A L, Dillon J F, Walker J, Hayes P C. The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J Hepatol 1995; 23: 254-8.